SANOFI has entered into an agreement to acquire Vicebio, a company formed in 2018 to develop the University of Queensland’s proprietary Molecular Clamp technology to make vaccines against life-threatening respiratory viral infections.

The US$1.6 billion (A$2.4 billion) deal is the largest involving a company that is commercialising intellectual property from an Australian university, and represents an opportunity for the technology to be accelerated through the final stages of translation into a vaccine to address global health challenges.

The post UQ vaccine tech in billion-dollar deal appeared first on Pharmacy Daily.